Zai Lab Forms $338 Million Collaboration with Schrödinger to Discover Oncology Drug

Shanghai 's Zai Lab and Schrödinger of New York formed a global collaboration to develop a novel oncology product targeting DNA damage. Schrödinger has developed a physics-based software platform to identify new drug candidates. Zai Lab will make an upfront payment to Schrödinger to fund part of Schrödinger's research costs. Schrödinger will be eligible to receive up to $338 million in milestone payments. Once a candidate is identified, Zai will assume responsibility for development, manufacturing and commercialization. More details.... Stock Symbols: (NSDQ: ZLAB; HKEX: 9688) (NSDQ: SDGR) Share this with colleagues: // //